February 2025 – Page 17

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

3 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation

Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

3 months ago talkbio0Tagged 2025, CagriSema, Drug Industry, Growth, Nordisk, Obesity, regulatory approval, Sales - occupational activity, Wegovy

Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval

NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community

3 months ago talkbio0Tagged beat, Bettis, Black Populations, Cardiovascular Diseases, Centers for Disease Control and Prevention (U.S.), Community, Foundations, heart health, Hypertensive disease, Jerome, NEFL gene

Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL

Boston Scientific’s Farapulse PFA System Surpasses $1 Billion in Revenue, Transforming Electrophysiology Market

3 months ago talkbio0Tagged Atrial Fibrillation, Boston Scientific, Electrophysiology (science), Farapulse, field ablation, innovation, Medical Devices, Revenue Milestone

Boston Scientific, Farapulse, pulsed field ablation, atrial fibrillation, electrophysiology, revenue milestone, medical device innovation

FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson’s Disease

3 months ago talkbio0Tagged apomorphine hydrochloride, Approved, Infusion procedures, motor fluctuations, Onapgo, Parkinson 's disease, subcutaneous, Supernus, United States Food and Drug Administration

Onapgo, apomorphine hydrochloride, Parkinson’s disease, subcutaneous infusion, motor fluctuations, FDA approval, Supernus Pharmaceuticals

FDA Halts Amgen’s Phase 1 Obesity Drug Trial: AMG 513 Study on Hold

3 months ago talkbio0Tagged AMG, amgen, Obesity, pharmaceutical setback, phase 1 trial, Study on Hold, United States Food and Drug Administration

Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback

FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment

3 months ago talkbio0Tagged Approved, Continuous Delivery, dimethylethylsilylimidazole, Macular edema due to diabetes mellitus, Ophthalmological implant, ranibizumab, Roche (company), Susvimo, United States Food and Drug Administration, Vision

Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement

Novo Nordisk Projects Slower Growth for 2025 Despite Wegovy’s Strong Q4 Performance

3 months ago talkbio0Tagged Drug Industry, Growth, Nordisk, Obesity, Sales - occupational activity, Wegovy

Novo Nordisk, Wegovy, obesity drugs, sales growth, 2025 outlook, pharmaceutical industry

Pharmaceutical Giants Bristol Myers Squibb and Kyowa Kirin Announce 119 Layoffs in New Jersey Amid Restructuring Efforts

3 months ago talkbio0Tagged cost-cutting, Drug Industry, Kirin, Kyowa, Myers, New Jersey, restructuring, squibb

Bristol Myers Squibb, Kyowa Kirin, layoffs, New Jersey, restructuring, pharmaceutical industry, cost-cutting, workforce reduction

J&J’s Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection

3 months ago talkbio0Tagged amivantamab, CHMP, Epidermal Growth Factor Receptor, Johnson & Johnson, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous formulation, United States Food and Drug Administration

Rybrevant, amivantamab, Johnson & Johnson, CHMP, FDA, subcutaneous formulation, non-small cell lung cancer, EGFR mutations